NASDAQ$CNTA
Centessa Pharmaceuticals plc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Centessa Pharmaceuticals reported financial results and business highlights.
Centessa Pharmaceuticals reported a net loss of $53.9 million for the third quarter of 2022, with cash and cash equivalents of $444.8 million as of September 30, 2022. The company is advancing its pivotal program for SerpinPC, planning to present Phase 2a OLE study data at ASH, and on track to submit the IND for LB101 in late 2022. The cash runway is expected to fund operations into 2026.
- Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 observation study on track to begin this quarter.
- Data readout of SerpinPC Phase 2a OLE Study with additional 18-months of continued subcutaneous treatment at ASH Annual Meeting in December 2022.
- IND submission for LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody, on track for late 2022.
- Cash runway into 2026 enables multiple clinical readouts across pipeline.
Headline financials
Revenue & EPS history
Centessa · Revenue · Quarterly
$0
Forward guidance
Centessa Pharmaceuticals expects its cash and cash equivalents to fund operations into 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.0%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+4.0%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+19.4%
Q2 2024
Best reaction
-14.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | -0.3% | +0.3% | |
| Q4 2025 | -4.2% | +6.1% | +45.9% | |
| Q3 2025 | -5.2% | -5.9% | +26.0% | |
| Q1 2025 | -1.2% | -1.6% | -0.6% | |
| Q4 2024 | -4.9% | -12.3% | -18.2% | |
| Q3 2024 | +8.1% | -4.4% | +0.8% | |
| Q2 2024 | +19.4% | +18.5% | +43.1% | |
| Q1 2024 | +0.8% | -1.1% | +8.1% | |
| Q4 2023 | -0.2% | +2.1% | -19.6% | |
| Q3 2023 | +6.8% | +13.4% | +7.1% | |
| Q2 2023 | +3.6% | -4.2% | +1.0% | |
| Q1 2023 | +0.2% | +0.9% | -0.4% | |
| Q4 2022 | -1.3% | -3.1% | +21.0% | |
| Q3 2022 | +5.3% | +4.7% | +15.1% | |
| Q2 2022 | -14.6% | -22.4% | -19.4% | |
| Q1 2022 | +2.0% | -15.7% | -21.1% | |
| Q4 2021 | -0.2% | +9.6% | -3.0% | |
| Q3 2021 | +2.5% | +9.3% | -9.9% | |
| Q1 2021 | +1.7% | +3.4% | +2.1% | |
| Q2 2021 | +1.7% | +3.4% | +2.1% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro